Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers
A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker
Sponsor: Bristol-Myers Squibb
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Bristol-Myers Squibb
Other Atrial Fibrillation trials with similar outcome
A PHASE1 clinical study on Atrial Fibrillation, this trial is terminated or withdrawn. The trial is conducted by Bristol-Myers Squibb and has accumulated 8 data snapshots since 2014. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2023 [monthly]
Terminated PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .